Regenerative Medical Solutions

Executive Summary

Regenerative Medical Solutions (RMS) is a privately-held biotechnology company headquartered in Tampa, Florida, developing a functional cure for diabetes using induced pluripotent stem cell (iPSC) technology. The company's core platform converts iPSCs into insulin-producing pancreatic islet cells, aiming to restore endogenous insulin production and eliminate lifelong insulin dependency for both Type 1 and Type 2 diabetes patients. Founded in 2012, RMS has focused on creating a scalable and cost-effective manufacturing process, addressing key challenges in cell therapy such as purity, potency, and immune rejection. The company targets a global diabetes population exceeding 500 million, positioning its therapy as a potential breakthrough in regenerative medicine if successful.

Upcoming Catalysts (preview)

• Q4 2027IND Filing and Phase 1 Trial Initiation50% success
• H1 2027Strategic Partnership or Licensing Deal with Major Pharma40% success
• Q2 2027FDA Regenerative Medicine Advanced Therapy (RMAT) Designation55% success